AKOS-22
Based on 1 Customer Validation
AKOS-22 is a potent mitochondrial protein VDAC1 (voltage-dependent anion channel 1) inhibitor (Kd=15.4 μM). AKOS-22 interacts with VDAC1 and inhibiting both VDAC1 oligomerization and apoptosis. AKOS-22 protects against mitochondrial dysfunction.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.23%
- CAS No.: 878983-38-1
- Formule: C22H21ClF3N3O3
- Masse moléculaire:467.87
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Reprogramming Compound Library
HY-L039
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mitochondria-Targeted Compound Library
HY-L089
-
Glucose Metabolism Compound Library
HY-L092
-
Cuproptosis Compound Library
HY-L133
-
Cancer Stem Cells Compound Library
HY-L135
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Metabolism/Protease Compound Library
HY-L012
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
Activité biologique
Kd: 15.4 μM (VDAC1)[1]
AKOS-22 (5-20 μM; 2 hours) inhibits both VDAC1 oligomerization and apoptosis in a concentration-dependent manner (IC50=7.5 μM)[1].
AKOS-22 inhibits selenite-induced VDAC1 oligomerization, Cyto c release and apoptosis in HEK-293 cells (IC50=3.3-3.6 μM). AKOS-22 (30 μM, 2 h) inhibits cisplatin-induced VDAC1 oligomerization and apoptosis in neuroblastoma cell line SH-SY5Y. AKOS-22 prevents the elevation of [Ca2+]I associated with apoptosis induction, and thus Ca2+ accumulation by the mitochondria[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 878983-38-1
-
Appearance Solid
-
Masse moléculaire 467.87
-
Formule C22H21ClF3N3O3
-
Color White to off-white
-
SMILES
O=C(C(N1CCC(NC2=CC=C(OC(F)(F)F)C=C2)CC1)C3)N(C4=CC=C(Cl)C=C4)C3=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 125 mg/mL (267.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1373 mL | 10.6867 mL | 21.3735 mL | 53.4336 mL |
| 5 mM | 0.4275 mL | 2.1373 mL | 4.2747 mL | 10.6867 mL | |
| 10 mM | 0.2137 mL | 1.0687 mL | 2.1373 mL | 5.3434 mL | |
| 15 mM | 0.1425 mL | 0.7124 mL | 1.4249 mL | 3.5622 mL | |
| 20 mM | 0.1069 mL | 0.5343 mL | 1.0687 mL | 2.6717 mL | |
| 25 mM | 0.0855 mL | 0.4275 mL | 0.8549 mL | 2.1373 mL | |
| 30 mM | 0.0712 mL | 0.3562 mL | 0.7124 mL | 1.7811 mL | |
| 40 mM | 0.0534 mL | 0.2672 mL | 0.5343 mL | 1.3358 mL | |
| 50 mM | 0.0427 mL | 0.2137 mL | 0.4275 mL | 1.0687 mL | |
| 60 mM | 0.0356 mL | 0.1781 mL | 0.3562 mL | 0.8906 mL | |
| 80 mM | 0.0267 mL | 0.1336 mL | 0.2672 mL | 0.6679 mL | |
| 100 mM | 0.0214 mL | 0.1069 mL | 0.2137 mL | 0.5343 mL |
AKOS-22 Related Classifications
HY-111217 Related Classifications
Powered by Bioz